PolTREG launches Phase 2 cell therapy trial in children with presymptomatic diabetes
Gdańsk, Poland – 24 October 2024 (07:00 CET) – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cellular therapies for a wide range of autoimmune diseases, has launched a placebo-controlled Phase 2 clinical trial with PTG-007 Treg cell therapy in presymptomatic type-1 diabetes (T1D) patients, after receiving approval from the European Medicines Agency. … Continued